Phibro Animal Health Corporation has announced a licensing agreement with Lighthouse Pharmaceuticals, Inc. for a novel therapeutic asset aimed at improving periodontal health in dogs. The agreement grants Phibro exclusive rights to develop, manufacture, and commercialize Lighthouse Pharma's proprietary compound for canine periodontal care. The compound, which has shown strong preclinical efficacy and safety, will be advanced through regulatory, commercial, and distribution channels by Phibro. Financial terms of the agreement were not disclosed.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Phibro Animal Health Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20251009727133) on October 09, 2025, and is solely responsible for the information contained therein.